, 2,201 patients were identified who underwent both prostate biopsy and RP between 2006 and 2016. Propensity score matching was performed with the nearest neighbor method using R-programming version 3.3.1 and a 4:1 match ratio. A total of 101 men were identified who underwent MRI-TRUS plus standard template biopsies were subsequently matched to 404 men who underwent untargeted extended template TRUS biopsy. Matched covariates included age at diagnosis, initial prostate specific antigen (PSA), race, clinical stage, total number of cores retrieved at time of biopsy, and history of prior TRUS biopsy. Continuous variables were compared using Wilcoxon rank-sum tests and categorical variables were assessed with c2 test. The concordance of Gleason score from biopsy to RP was assessed.
INTRODUCTION AND OBJECTIVES:
The use of pre-biopsy MRI for risk stratification of men with no previous history of prostate biopsy remains controversial due to concerns of missed high grade cancers among men with low suspicion MRI. We evaluated the relationship of pre-biopsy MRI and MRI-ultrasound fusion-targeted prostate biopsy (MRF-TB) outcomes among men with no previous history of prostate biopsy.
METHODS: Between 6/2012 and 9/2016, 1584 consecutive men presenting to our institution for prostate biopsy underwent pre-biopsy MRI followed by MRF-TB and systematic biopsy (SB), and were prospectively enrolled in an IRB-approved database. We evaluated the outcomes of 800/1584 men who had no previous biopsy. 109 men were excluded due to outside MRI, 1.5T MRI, or hip implants. 35 men were excluded as they did not undergo concomitant SB with MRF-TB. Men with no MRI lesion (MRI score of 1) underwent only SB.
RESULTS: Among 656/800 men who met inclusion criteria (mean age 63AE11 years; mean PSA 6.1AE3.4 ng/mL), prostate cancer (PCa) was detected in 380 (58%) cases. Cancer detection rates (CDR) for SB and MRF-TB were 54% and 43%, respectively (p < 0.01). MRF-TB detected significantly less Gleason (GS) 6 PCa compared to SB [86/ 203 (42%) (Table 2) , detection of GS 3+4 and GS !4+3 in men with an MRI score of 1 or 2 is less than 5%. Deferral of prostate biopsy in 229 men with an MRI score of 1 or 2 would have missed 3% (7) of GS !4+3, 5% (11) of GS 3+4, and 28% (63) of GS 6 PCa, of which 75% (47/63) would have been clinically insignificant by Epstein criteria.
CONCLUSIONS: In men presenting for primary prostate biopsy, MRF-TB detects more GS 3+4 PCa than SB and reduces overdetection of GS 6 by 49%. Deferral of primary prostate biopsy in men with MRI scores of 1 or 2 would miss very few clinically significant PCa while avoiding over-detection of clinically insignificant disease in 21% of these men. METHODS: Retrospective analysis across two Australian tertiary referral centres between 2012 and 2016 was performed. Patients underwent 3-Tesla mpMRI followed by prostate biopsy 3 months later, by cognitive or software fusion, with either transrectal or transperineal ultrasound guided techniques.
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